ETP Capital (Emerging Technology Partners, LLC) is a fund management company focused on primary market investments in the biopharmaceutical sector. Established in 2000, the firm is dedicated to investing in biotechnology startups centered on gene cloning, gene silencing, and antibody-based technologies. Its notable portfolio companies include publicly listed firms such as Human Longevity, Genetron Health, CASI Pharmaceuticals, and others.